David Thompson
Corporate Officer/Principal bij INOZYME PHARMA, INC.
Profiel
David Thompson is the founder of Azure Biotech, Inc. He is currently a Member-Scientific Advisory Board & Senior Advisor at Inozyme Pharma, Inc. His former position at Inozyme Pharma, Inc. was Chief Scientific Officer & Senior Vice President from 2018 to 2020.
Dr. Thompson has a graduate and doctorate degree from the University of Connecticut and a graduate degree from The University of Montana.
Actieve functies van David Thompson
| Bedrijven | Functie | Begin |
|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 01-07-2021 |
Eerdere bekende functies van David Thompson
| Bedrijven | Functie | Einde |
|---|---|---|
| INOZYME PHARMA, INC. | Hoofd Techniek/Wetenschap/O&O | 13-10-2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Oprichter | - |
Opleiding van David Thompson
| University of Connecticut | Doctorate Degree |
| The University of Montana | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
